Skip to main content

AL-S Pharma was founded in 2016 by Neurimmune and TVM Capital Life Science to develop AP-101 for the treatment of ALS

AP-101 was originally discovered using Neurimmune’s Reverse Translational Medicine platform — a clinically validated technology for generating human antibodies that target misfolded proteins implicated in neurodegenerative diseases.

AL-S Pharma brings together a seasoned team of biotech and pharmaceutical leaders with expertise spanning drug discovery, translational research, and clinical development. Based on the successful Phase 2 data, we are now advancing AP-101 into Phase 3 and preparing for late-stage development with the goal of delivering a disease-modifying therapy for ALS.

Team

Michael Salzmann, PhD
Chief Executive Officer
Angela Genge, MD
Chief Medical Officer
Fabian Buller, PhD
Chief Business Officer
Dirk Schimkat, lic.rer.pol
Chief Financial Officer
Paule Clermont, MSc
Clinical Operations
Bryan Boggs, Pharm.D.
Regulatory Affairs
Rakhee Ganti, PhD
Medical Affairs
Emma Bowden, PhD
SVP Clinical Development
Christian Somandin, PhD
CMC
Kevin Meyer, PhD
Business Development

Board of Directors

Hubert Birner, PhD, MBA
TVM Capital
Jan Grimm, PhD
Neurimmune
Marc Rivière, MD
TVM Capital
Prof. Christoph Hock, MD
Neurimmune
Prof. Guy Rouleau, MD
Mc Gill

«I was drawn to AL-S Pharma by the scientific rigor and patient-centered mission driving the development of AP-101. Targeting misfolded SOD1 offers a promising and differentiated path in ALS, and I’m proud to help lead its clinical advancement on behalf of patients.»

Angela Genge, MD
Chief Medical Officer

«At AL-S Pharma, we are driven by the urgent need for effective therapies in ALS. The progress of AP-101 reflects our commitment to translating scientific innovation into clinical advances for patients and families affected by this devastating disease.»

Michael Salzmann, PhD
Chief Executive Officer

    Co-created by